Spinnovation launch new biologics division with unique service provision
Frederic Girard, CEO Spinnovation Analytical BV announced the launch of a new division of the company – Spinnovation biologics – at the annual meeting of the Flanders Biotech group. Extending the company’s current contract research and contract analysis services, the new division will provide a unique mix of services for spent culture media analysis, and the profiling and characterization of biologics and biosimilars.
Dr Girard said, “With this exciting launch of the Biologics division we aim to further our commitment to bringing rapid solutions for the problems faced by our clients. The new core service; spent media analysis with Spedia-NMR™, is unique and can deliver a step-fold increase in throughput and detail over standard methods, in as few as five working days. We know that our cost-effective package, delivered through flexible service agreements, is exactly what our pharma and biotech customers need.”
Other news from the department business & finance
